Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC.
published in: Journal of Thoracic Oncology
date of publication: 2016-02-17
Cites articles
There is nothing here
Article - wd:Q39980379
There is nothing here
Article - wd:Q39980379